Company: DHR
Filing Date: 2025-10-21
Form Type: 10-Q
Source: 0000313616-25-000182
Chunk: 91

Company: DANAHER CORP /DE/
Filing Date: 2025-10-21
Form: 10-Q
Item: Item 8
Chunk 91
---
,948 The carrying value of goodwill by segment is summarized as follows ($ in millions):September 26, 2025December 31, 2024Biotechnology$23,145 $21,437 Life Sciences12,837 12,305 Diagnostics6,966 6,755 Total$42,948 $40,497 

14

The Company reviews identified intangible assets for impairment whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable.  During the third quarter of 2024, the Company concluded that it had an impairment indicator for an indefinite-lived trade name within the genomics consumable business included in the Life Sciences segment, primarily as a result of softness in the genomics market, including but not limited to the discontinuation of certain drug development programs announced in the third quarter of 2024, weaker demand at some of the business’s larger customers as well as reduced demand due to the reprioritization of drug development programs at other customers.  The Company engaged a third-party valuation specialist to assist in the valuation of the trade name using a relief from royalty method of valuation.  The significant assumptions in the relief from royalty method included, but were not limited to, revenue, revenue growth rates, planned use of the trade name, royalty rates and discount rates.  The Company recorded a noncash impairment charge of $222 million pretax ($169 million after-tax) related to the trade name for the three and nine-month periods ended September 27, 2024, which is included in selling, general and administrative expenses in the accompanying Consolidated Condensed Statements of Earnings.  During the second quarter of 2025, the Company decided to reorganize and integrate certain businesses within its Life Sciences segment to better serve the Company’s customers in new market segments and to respond to current market conditions.  As a result of these plans, the Company concluded that the same indefinite-lived trade name within the genomics consumables business was no longer considered to be indefinite-lived, resulting in an impairment indicator.  The Company engaged a third-party valuation specialist to assist in the valuation of the trade name using a relief from royalty method of valuation.  The Company recorded a noncash impairment charge of $432 million pretax ($328 million after-tax) related to the trade name for the nine-month period ended September 26, 2025, which is included in selling, general and administrative expenses in the accompanying Consolidated Condensed Statements of Earnings.